Irritable bowel syndrome – a common problem, individual approach

2021 ◽  
Vol 14 (4) ◽  
pp. 369-374
Author(s):  
Barbara Skrzydło-Radomańska ◽  
Bartosz J. Sapilak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Recurrent Abdominal Pain ◽  
Frequency Change ◽  
High Fiber ◽  
Fiber Diet ◽  
Bowel Movements ◽  
Irritable Bowel ◽  
Effective Drugs

Irritable bowel syndrome is a recurrent abdominal pain that occurs at least once a week for 3 months, with symptoms at least 6 months associated with at least two features: bowel movements, change in bowel frequency, change in the appearance of stools. According to the Rome IV Diagnostic Criteria, the disease is diagnosed on the basis of clinical symptoms. This does not apply to people over 50 years of age (and in the case of first-degree relatives of patients with colorectal cancer after 45 years of age) and patients with alarm symptoms. Due to the lack of a single etiological factor, the treatment of irritable bowel syndrome consists in reducing symptoms and improving the patient’s quality of life. Non-pharmacological treatment includes a high-fiber diet and modification of the microbiota. The most effective drugs are antispasmodics directly affecting the smooth muscle, inhibiting the influx of calcium, i.e. drotaverine, mebeverine and alverine. There has been proven effectiveness of antidepressants. This confirms that functional disorders of the gastrointestinal tract are a manifestation of the dysfunction of the brain–gut–microbiota axis.

Association of Serum Vitamin D Concentration With Clinical Symptoms and Quality of Life in Patients With Irritable Bowel Syndrome

2018 ◽  
Vol 38 (4) ◽  
pp. 327-333 ◽  
Author(s):  
Amir Abbasnezhad ◽  
Reza Amani ◽  
Amin Hasanvand ◽  
Esmaeil Yousefi Rad ◽  
Meysam Alipour ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Serum Vitamin ◽  
Serum Vitamin D ◽  
Irritable Bowel

Adequate Relief as an Endpoint in Clinical Trials in Irritable Bowel Syndrome

1998 ◽  
Vol 26 (2) ◽  
pp. 76-81 ◽  
Author(s):  
AW Mangel ◽  
BA Hahn ◽  
AT Heath ◽  
AR Northcutt ◽  
S Kong ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Bowel Function ◽  
Recurrent Abdominal Pain ◽  
Response To Therapy ◽  
Multiple Parameters ◽  
Severity Scores ◽  
Irritable Bowel

Irritable bowel syndrome is characterized by recurrent abdominal pain and altered bowel function. In designing studies to evaluate new treatments for this disease, however, it is difficult to select appropriate endpoints to reflect improvement in the range of symptoms of the syndrome. In the present study we evaluated the parameter of adequate relief of abdominal pain and discomfort, as perceived by the patients, as a key endpoint for efficacy in the treatment of patients with irritable bowel syndrome. Abdominal pain and bowel function data were collected daily from 370 patients with the disease during treatment with placebo or a novel potent 5HT3 receptor antagonist. Once every 7 days adequate relief of pain and discomfort was assessed. Quality-of-life data were collected using self-administered questionnaires. The endpoint of adequate relief was significantly ( P < 0.05) correlated with improvement in pain severity scores, percentage of pain-free days, percentage of days with urgency, improvement in stool frequency and consistency, and quality-of-life parameters. Adequate relief of pain and discomfort is significantly correlated with changes in multiple parameters associated with irritable bowel syndrome and can be used as an endpoint for assessing response to therapy in these patients.

Effects of a high-fiber diet on symptoms of irritable bowel syndrome: A randomized clinical trial

Nutrition ◽  
2004 ◽  
Vol 20 (9) ◽  
pp. 735-737 ◽  
Author(s):  
Rocio Aller ◽  
Daniel Antonio de Luis ◽  
Olatz Izaola ◽  
Fernando la Calle ◽  
Lourdes del Olmo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Randomized Clinical Trial ◽  
High Fiber ◽  
Fiber Diet ◽  
High Fiber Diet ◽  
Irritable Bowel

scholarly journals INTERVENTIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW OF COCHRANE SYSTEMATIC REVIEWS

2021 ◽  
Vol 58 (1) ◽  
pp. 120-126
Author(s):  
Ana Carolina Lemes SCACIOTA ◽  
Delcio MATOS ◽  
Manuelle Mastrorocco Brand ROSA ◽  
Mileny Esbravatti Stephano COLOVATI ◽  
Elisa Fatima Benavent Caldas BELLOTTO ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Systematic Reviews ◽  
Clinical Symptoms ◽  
Gastrointestinal Disorder ◽  
Cochrane Library ◽  
Psychological Interventions ◽  
Cochrane Database ◽  
Long Term Follow Up ◽  
Irritable Bowel

ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) is a complex gastrointestinal disorder, whose understanding is relatively uncertain, and the treatment guidance decision still represents a challenge. OBJECTIVE: To identify and critically appraise systematic reviews (SRs) published in the Cochrane Database of SRs (CDSR) on the effects of interventions (pharmacological and non-pharmacological) for the treatment of IBS. METHODS: The search was conducted at the Cochrane Library in May 2020. The methodological quality of the SRs was evaluated by the AMSTAR-2 tool. RESULTS: Eight SRs with moderate to high quality were included, which addressed the treatments: (a) pharmacological: volume agents, antispasmodics, antidepressants and tegaserod; and (b) non-pharmacological: homeopathy, acupuncture, phytotherapy, biofeedback, psychological interventions and hypnotherapy. The results were favorable to antispasmodic drugs and antidepressants regarding the improvement of clinical symptoms. There was no difference between volume agents or tegaserod when compared to placebo. Acupuncture and homeopathy showed a little improvement in symptoms compared to placebo, but the certainty of this evidence was considered low to very low. Psychological interventions seem to improve the overall assessment of the patient and relief symptoms such as abdominal pain. However, there was no long-term follow-up of these patients. The results of the other treatments were considered uncertain due to the high risk of bias. CONCLUSION: Considering the low quality of the studies included in the SRs, pharmacological treatment with antispasmodics and antidepressants seems to be beneficial for patients with IBS. Among non-pharmacological interventions, psychological interventions seem to be beneficial. However, further clinical trials are recommended with greater methodological rigor to prove these findings.

Sex-Related Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome

2017 ◽  
Vol 62 (6) ◽  
pp. 1550-1560 ◽  
Author(s):  
Razieh Choghakhori ◽  
Amir Abbasnezhad ◽  
Reza Amani ◽  
Meysam Alipour
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Clinical Symptoms ◽  
Irritable Bowel

Serum Levels of Chemerin, Apelin, and Adiponectin in Relation to Clinical Symptoms, Quality of Life, and Psychological Factors in Irritable Bowel Syndrome

2020 ◽  
Vol 54 (5) ◽  
pp. e40-e49
Author(s):  
Mohammad A. Baram ◽  
Amir Abbasnezhad ◽  
Koroush Ghanadi ◽  
Khatereh Anbari ◽  
Razieh Choghakhori ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Psychological Factors ◽  
Clinical Symptoms ◽  
Serum Levels ◽  
Irritable Bowel

scholarly journals Comparative evaluation of efficacy of Pinaverium monotherapy and combination therapy of Pinaverium with itopride hydrochloride in patients with cross irritable bowel syndrome with constipation and postpradial distress syndrome

2019 ◽  
Vol 3 (20) ◽  
pp. 54-57
Author(s):  
O. V. Krapivnaya ◽  
S. A. Alekseenko
Keyword(s):  
Irritable Bowel Syndrome ◽  
Combination Therapy ◽  
Distress Syndrome ◽  
Clinical Symptoms ◽  
Rome Iii Criteria ◽  
Sf 36 ◽  
Rome Iii ◽  
Itopride Hydrochloride ◽  
Irritable Bowel

Forty-seven patients with overlap between irritable bowel syndrome with constipation and (IBS-C) and postpradial distress syndrome (PDS) complying with Rome III criteria were treated with pinaverium in combination with itopride and 58 patients with IBS-C-PDS overlap were treated with pinaverium for 4 weeks. Clinical symptoms and quality of life by SF-36 were estimated at baseline and after 4 weeks of treatment. Pinaverium and Itopride combination therapy significantly improved both IBS-C and PDS-like symptoms, and SF-36 scores when compared to Pinaverium monotherapy over a 4-week period.

Effect of a synbiotic, ColonFit, in patients with irritable bowel syndrome, functional constipation and functional diarrhea

2020 ◽  
Vol 74 (6) ◽  
pp. 535-542
Author(s):  
Radek Kroupa ◽  
Jiří Jarkovský ◽  
Barbora Packová ◽  
Šárka Doležalová ◽  
Hana Junková ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Constipation ◽  
Bowel Symptoms ◽  
Functional Diarrhea ◽  
Initial Symptoms ◽  
Bowel Diseases ◽  
Bowel Movements ◽  
Bristol Stool Scale ◽  
Irritable Bowel

Background: Supplementary dietary fiber and probiotics may improve bowel symptoms due to changes in microbiome and fermentation. The aim of the study was the evaluation of symbiotic with psyllium, ColonFit, in patients with functional colonic diseases. Patients and Methods: A prospective observational study in patients with irritable bowel syndrome, functional constipation and functional diarrhea for a 4-week intake of ColonFit 10 g daily. The type and severity of bowel symptoms (scale 1–5), number and consistency of stool and quality of life features were analyzed in subgroups according to dominant initial symptoms. Results: Complete data were available from 110 patients (mean age 49.9 ± 15.3 years, 58.2% females). Constipation related symptoms were predominant in 46 (41.8%) patients, diarrhea in 28 (25.5%) and mixed type in the rest. The symptoms in constipation predominant group were more severe than in others. The significant change in softening of stool consistency (from 1.9 to 3.8 in Bristol stool scale; p < 0.001), an increase in spontaneous bowel movements (from 3.1 to 5.6× weekly; p = 0,001) and reduction of incomplete bowel movements of 40% and abdominal pain of 42% were observed in constipated patients. The reduction in a number of bowel movement per week (from 17.8 to 13.6; p = 0.001) and improvement of abdominal cramps by 27% and reduction of dietary limitations by 30% were recorded in diarrhea subgroup. The beneficial effect lasted for a two-week follow up after the discontinuation of ColonFit use. Conclusion: The ColonFit use was most beneficial in constipated patients. The improvement of several symptoms was observed in other subtypes of irritable bowel syndrome without any worsening of troubles. The use of the combination of psyllium, inulin and probiotics may offer an effective alternative for the management of functional bowel diseases.

Sign in / Sign up

Export Citation Format

Share Document